Jazz Pharmaceuticals
JAZZ
323 hedge funds and large institutions have $7.32B invested in Jazz Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 63 funds opening new positions, 101 increasing their positions, 105 reducing their positions, and 40 closing their positions.
58% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 40
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
7% more funds holding
Funds holding: 303 → 323 (+20)
0.56% less ownership
Funds ownership: 91.36% → 90.8% (-0.56%)
4% less repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 105
9% less capital invested
Capital invested by funds: $8.03B → $7.32B (-$710M)
68% less call options, than puts
Call options by funds: $16.5M | Put options by funds: $51.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Boston Partners
Boston,
Massachusetts
|
+$166M |
| 2 |
Bank of New York Mellon
New York
|
+$38M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$36.8M |
| 4 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$24.5M |
| 5 |
Goldman Sachs
New York
|
+$23.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$160M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$76.2M |
| 3 |
PC
Polar Capital
London,
United Kingdom
|
-$52.8M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
-$41.1M |
| 5 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
-$33.5M |
JAZZ Hedge Fund Activity: Q4 2017 in Review
323 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q4 2017, worth a combined $7.32B — down 8.8% from $8.03B a quarter earlier.
Buyers outnumbered sellers: 63 funds opened new JAZZ positions and 40 closed out — a net gain of 23 holders — while 101 added to existing stakes and 105 trimmed.
The largest buyer was Boston Partners, opening a new position worth an estimated $166M. The largest seller was Fidelity Investments, cutting an estimated $160M.
- 323 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q4 2017, up from 303 in Q3 2017.
- Funds reported $7.32B of Jazz Pharmaceuticals stock for Q4 2017, down 8.8% quarter-over-quarter.
- 63 funds opened new Jazz Pharmaceuticals positions in Q4 2017 and 40 closed out, a net change of +23 holders.
- The largest Jazz Pharmaceuticals buyer in Q4 2017 was Boston Partners, an estimated $166M added.
- The largest Jazz Pharmaceuticals seller in Q4 2017 was Fidelity Investments, an estimated $160M sold.
Based on aggregated 13F filings for Q4 2017.